GlassScriptPhysician profile
Molly E Sonenklar
NPI 1780003798
$719.52
in general payments reported to CMS, 2019-2025
10 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $146 · 2023: $236 · 2024: $77.74 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $189.73 | 2024-2025 | Alhemo |
| Genetix Biotherapeutics INC | $178.67 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $146.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $50.38 | 2023 | |
| Pfizer INC. | $33.41 | 2025 | |
| Y-Mabs Therapeutics, INC. | $30.84 | 2025 | Danyelza |
| Csl Behring | $25.68 | 2023 | Hemgenix |
| Alexion Pharmaceuticals, INC. | $22.66 | 2024 | Ultomiris |
| Servier Pharmaceuticals LLC | $21.35 | 2025 | |
| Genentech USA, INC. | $20.56 | 2024 | Hemlibra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Sonenklar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.